Gyre Therapeutics, Inc.GYRENASDAQ
Loading
Year-over-year operating cash flow growth rate
Percentile
P5
Near historical low
vs 3Y Ago
-2.8x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -220.30% |
| Q3 2025 | 123.95% |
| Q2 2025 | 1718.60% |
| Q1 2025 | 95.32% |
| Q4 2024 | -264.56% |
| Q3 2024 | 129.86% |
| Q2 2024 | -294.59% |
| Q1 2024 | -14.17% |
| Q4 2023 | -55.68% |
| Q3 2023 | 67.26% |
| Q2 2023 | -56.48% |
| Q1 2023 | 806.24% |
| Q4 2022 | 79.73% |
| Q3 2022 | 40.81% |
| Q2 2022 | -2.02% |
| Q1 2022 | 31.83% |
| Q4 2021 | 18.17% |
| Q3 2021 | -7.34% |
| Q2 2021 | 17.38% |
| Q1 2021 | -10.14% |
| Q4 2020 | -70.00% |
| Q3 2020 | 14.06% |
| Q2 2020 | -215.99% |
| Q1 2020 | 40.78% |
| Q4 2019 | 11.11% |
| Q3 2019 | 20.63% |
| Q2 2019 | 23.35% |
| Q1 2019 | -66.00% |
| Q4 2018 | -28.33% |
| Q3 2018 | 5.27% |
| Q2 2018 | -45.15% |
| Q1 2018 | 19.15% |
| Q4 2017 | -28.16% |
| Q3 2017 | -11.97% |
| Q2 2017 | -2.56% |
| Q1 2017 | 13.76% |
| Q4 2016 | 2.58% |
| Q3 2016 | -40.28% |
| Q2 2016 | 23.23% |
| Q1 2016 | 7.74% |